Impact of direct antiviral agents for hepatitis C virus -induced liver diseases on registration, waiting list and liver transplant activity in France - 06/10/23
, Carine Jasseron b, Camille Legeai b, Filomena Conti c, Christophe Duvoux d, Nassim Kamar e, Sébastien Dharancy f, Corinne Antoine b, ⁎ collaborators1
Highlights |
• | Direct-acting antivirals has dramatically improved the prognosis of liver transplantation candidates for HCV end-stage liver disease. |
• | Their availability is associated with a significant decrease of registration for liver transplantation, death and drop out for worsening condition in France. |
• | It has also decreased the number of transplantation for HCV end-stage liver disease and improved the 1-year graft survival in France. |
Abstract |
Direct-acting antivirals (DAA) has dramatically improved the prognosis of liver transplantation (LT) candidates for HCV end-stage liver disease (ESLD). We aimed to evaluate the impact of DAA on waiting list (WL) registration and LT activity in France.
We evaluated all patients registered to the French WL for HCV ESLD between 2000 and 2018. Timespan was divided into two periods according to DAA availability: 2010–2013 versus 2014–2018. Changes in the indications of LT, outcome on WL were evaluated. Then, we evaluated the activity of LT and outcome for HCV recipients in France.
Among 3,173 HCV candidates, registration on WL decreased by 33% between 2013 and 2018. The 1-year waitlist survival increased from 76.9% (95%CI: 74.2%-79.4%) in 2010–2013 to 79.8% (95%CI: 77.2%-82.1%) in 2014–2018 (p < 0.01). Regarding LT activity, the part of HCV ESLD decreased from 26% in 2010 to 16% in 2018. The 1-year graft survival rate in HCV recipients increased from 76.9% (95%CI: 73.7%-79.7%) in 2010–2012 to 84.9% (95%CI: 82.9%-86.7%) in 2013–2018 (p < 0.01).
The availability of DAA to treat HCV infection is associated with a significant decrease of registration for LT, death and drop out for worsening condition on the LT. In addition, it has decreased the number of HCV+ LT and improved the 1-year graft survival in France.
Le texte complet de cet article est disponible en PDF.Keywords : Liver transplantation, HCV, Waiting list, Allocation system, Treatment, DAA
Abbreviations : ABM, DAA, HCC, HCV, LT, MELD
Plan
Vol 47 - N° 8
Article 102168- octobre 2023 Retour au numéro
Article précédent
- Transjugular Intrahepatic Portosystemic Shunt is effective to treat portal hypertension due to sinusoidal obstructive syndrome
- Lina Hountondji, Dimitri Pureur, Melchior Chabannes, Sophie Felix, Thierry Thévenot
- Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study
- Yahong Chen, Xueqing Yang, Xiawei Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?